Compounds > rb 6145
Page last updated: 2024-09-03

rb 6145 and Benign Neoplasms

rb 6145 has been researched along with Benign Neoplasms in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Adams, GE; Stratford, IJ1
Stratford, IJ1
Adams, GE; Bremner, JC; Edwards, HS; Fielden, EM; Stratford, IJ1

Reviews

1 review(s) available for rb 6145 and Benign Neoplasms

ArticleYear
Bioreductive drugs in cancer therapy.
    BJR supplement, 1992, Volume: 24

    Topics: Animals; Antineoplastic Agents; Antioxidants; Cell Hypoxia; Humans; Misonidazole; Neoplasms; Nitroimidazoles; Prodrugs; Radiation-Sensitizing Agents; Tirapazamine; Triazines

1992

Other Studies

2 other study(ies) available for rb 6145 and Benign Neoplasms

ArticleYear
Bioreductive drugs for cancer therapy: the search for tumor specificity.
    International journal of radiation oncology, biology, physics, 1994, May-15, Volume: 29, Issue:2

    Topics: Animals; Antineoplastic Agents; Humans; Neoplasms; Nitric Oxide; Nitroimidazoles; Oxidation-Reduction; Photochemotherapy; Porfiromycin; Prodrugs; Tirapazamine; Triazines

1994
Nitroheterocyclic compounds as radiation sensitizers and bioreductive drugs.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 1991, Volume: 20 Suppl 1

    Topics: Antineoplastic Agents; Combined Modality Therapy; Humans; Misonidazole; Neoplasms; Nitroimidazoles; Radiation-Sensitizing Agents

1991